Aim. To study the efficiency of using alfuzosin 10 mg (Alfuprost® MR, SUN Pharma) in routine clinical practice in order to predict its feasibility for treating acute urinary retention.
Materials and methods: A total of 47 patients, aged from 54 to 88 years old (mean 68.5±5.6) with acute urinary retention due to benign prostatic hyperplasia were treated at the urology department of City clinical hospital named after D.D. Pletnev from September to December 2019. 14 patients were excluded from the study since they had chronic urinary retention. In all cases, urethral catheter was put and left in place for 24-72 hours (mean 44±12). All 33 patients were prescribed alfuzosin 10 mg. After removal of the urethral catheter, spontaneous voiding was restored in 19 patients. Transurethral resection of the prostate was consequently performed in three patients. In one patient, the urethral catheter was changed to cystostomy tube due to the urethritis. Recurrent urinary retention occurred in 10 men, and 8 patients underwent cystostomy. In other two cases, spontaneous voiding was restored after repeated removal of the urethral catheter.
Results: the efficiency of conservative therapy was 63.6% (21/33). According to our results, history of severe lower urinary tract symptoms, the prostate volume more than 50 cc and intravesical protrusion of more than 1 cm have a significant influence on the outcome of conservative therapy in patients with acute urinary retention.
Conclusions: Based on a prospective study, a high efficiency and safety of the Alfuprost® MP 10 mg/day in patients with acute urinary retention was established.

Keywords: benign prostatic hyperplasia, alpha-blockers, acute urinary retention, alfuzosin